# LoTam low-dose tamoxifen

Source: https://onco.cc/trials/nct06671912/  
OnCo record `nct06671912` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

LoTam compares low-dose tamoxifen with usual hormone therapy after early breast cancer. The registry currently marks the study suspended.

## Summary

LoTam compares low-dose tamoxifen with usual hormone therapy after early breast cancer. The registry currently marks the study suspended.

Interventional study registered as NCT06671912, sponsored by Alliance for Clinical Trials in Oncology. Registry phase: 3. Registry enrollment is 1,556 participants (estimated). Registry status checked October 10, 2026: suspended. UCSF lists this study as closed to local enrollment; local availability and overall registry status are separate. See the registry for full eligibility and current sites.

## Fields

- Kind: Trial
- Last checked: 2026-10-10
- Also known as: Testing Low Dose Tamoxifen for Invasive Breast Cancer, LoTam Trial
- Tags: ucsf-breast-coverage; interventional
- Registry id: NCT06671912
- Phase: 3
- Setting: Postmenopausal hormone receptor-positive, HER2-negative early breast cancer
- Sponsor: Alliance for Clinical Trials in Oncology

## Sources

- ClinicalTrials.gov NCT06671912: https://clinicaltrials.gov/study/NCT06671912
- UCSF study listing and local availability: https://clinicaltrials.ucsf.edu/trial/NCT06671912

## Connected records

- cancers: [Breast cancer (all types)](https://onco.cc/cancers/breast-cancer/)
- drugs: [Anastrozole](https://onco.cc/drugs/anastrozole/), [Exemestane](https://onco.cc/drugs/exemestane/), [Letrozole (and other aromatase inhibitors)](https://onco.cc/drugs/letrozole/), [Tamoxifen](https://onco.cc/drugs/tamoxifen/)
- institutions: [UCSF Helen Diller Family Comprehensive Cancer Center](https://onco.cc/institutions/ucsf/)

---
JSON: https://onco.cc/api/v1/entities/nct06671912.json